These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11023319)

  • 1. National service framework for coronary heart disease. Target of lowering cholesterol by 30% needs to be justified.
    Cracknell P
    BMJ; 2000 Sep; 321(7261):634. PubMed ID: 11023319
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical prevention of coronary heart disease through cholesterol-lowering therapy.
    Grundy SM
    Curr Ther Endocrinol Metab; 1997; 6():520-6. PubMed ID: 9174799
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimal management of cholesterol levels and the prevention of coronary heart disease in women.
    Mosca LJ
    Am Fam Physician; 2002 Jan; 65(2):217-26. PubMed ID: 11820486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial on CHD.
    Riesen WF
    J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S1-2. PubMed ID: 9044998
    [No Abstract]   [Full Text] [Related]  

  • 5. Cholesterol lowering drugs.
    Amarasingham R
    N Z Med J; 1990 Aug; 103(895):380. PubMed ID: 2385410
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimal age for starting lipid lowering treatment. A 10 year risk of 30% should be used.
    Simpson WG; Twomey P
    BMJ; 2000 Sep; 321(7261):637; author reply 638. PubMed ID: 11023327
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia.
    Svilaas A; Strandberg T; Eriksson M; Hildebrandt P; Westheim A
    Scand Cardiovasc J; 2008 Aug; 42(4):279-87. PubMed ID: 18609053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study.
    Zou Y; Hu D; Yang X; Xu Z; Cui L; Liu X; Wei Y; Gao M
    Chin Med J (Engl); 2003 Jun; 116(6):853-6. PubMed ID: 12877794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of dyslipidemia in the emergency department: impact of cholesterol testing on subsequent therapy.
    Blomkalns AL; O'Connell EM; Eady CE; Lindsell CJ; Gibler WB
    Am Heart J; 2006 Dec; 152(6):1182-6. PubMed ID: 17161073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why some patients respond poorly to statins and how this might be remedied.
    Thompson GR; O'Neill F; Seed M
    Eur Heart J; 2002 Feb; 23(3):200-6. PubMed ID: 11792134
    [No Abstract]   [Full Text] [Related]  

  • 11. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M
    Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment.
    Hyre AD; Fox CS; Astor BC; Cohen AJ; Muntner P
    Am J Kidney Dis; 2007 Jan; 49(1):37-45. PubMed ID: 17185144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alcohol use, vascular disease, and lipid-lowering drugs.
    Kolovou GD; Salpea KD; Anagnostopoulou KK; Mikhailidis DP
    J Pharmacol Exp Ther; 2006 Jul; 318(1):1-7. PubMed ID: 16627749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive lipid-lowering therapy in patients with coronary heart disease.
    Lauderdale SA; Sheehan AH
    Ann Pharmacother; 2005 Feb; 39(2):329-34. PubMed ID: 15613464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evidence for lipid lowering: type 2 diabetes and coronary heart disease risk.
    Townsend D; Davis R
    Prof Nurse; 2004 Jun; 19(10):38-40. PubMed ID: 15233071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk reduction strategies in coronary artery disease.
    Gibson TM; Ratts T
    J La State Med Soc; 2001 Jun; 153(6):312-9. PubMed ID: 11480382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on lipid-lowering therapy and LDL-cholesterol targets.
    Wiviott SD; Cannon CP
    Nat Clin Pract Cardiovasc Med; 2006 Aug; 3(8):424-36. PubMed ID: 16874355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy for dyslipidemia.
    Spellman CW
    J Am Osteopath Assoc; 2003 Jan; 103(1 Suppl 1):S9-11. PubMed ID: 12572624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.